Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2022
Journal Article
Current approaches to the diagnosis and management of amyloidosis
Taylor, Mark S., Sidiqi, Hasib, Hare, James, Kwok, Fiona, Choi, Bo, Lee, Darren, Baumwol, Jay, Carroll, Antonia S., Vucic, Steve, Neely, Pat, Korczyk, Dariusz, Thomas, Liza, Mollee, Peter, Stewart, Graeme J. and Gibbs, Simon D. J. (2022). Current approaches to the diagnosis and management of amyloidosis. Internal Medicine Journal, 52 (12), 2046-2067. doi: 10.1111/imj.15974
2022
Conference Publication
Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji K., Bahlis, Nizar Jacques, Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Pei, Huiling, Gupta, Niodita, Kaila, Shuchita, Matt, Kathryn, Gries, Katharine S., Carson, Robin, Borgsten, Fredrik and Weisel, Katja (2022). Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-165524
2022
Conference Publication
A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)
Roussel, Murielle, Mollee, Peter, Huart, Antoine, Sidiqi, Hasib, Horvath, Noemi, Karlin, Lionel, Jacquet, Caroline, Morel, Pierre, Leyronnas, Cecile, Bender, Sebastien, Bridoux, Frank, Jaccard, Arnaud and Gibbs, Simon D. (2022). A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP). 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166337
2022
Conference Publication
An individualized exercise intervention improves quality of life for people with multiple myeloma: The MyeEx randomized waitlist-controlled trial
Nicol, Jennifer L., Hill, Michelle M., Cunningham, Brent, Woodrow, Carmel, Adlard, Kirsten, Mollee, Peter, Weber, Nicholas, Nicol, Andrew J. and Skinner, Tina L. (2022). An individualized exercise intervention improves quality of life for people with multiple myeloma: The MyeEx randomized waitlist-controlled trial. COSA's 49th Annual Scientific Meeting Equitable Cancer Care for All: Gender, Identity, Culture, Geography, and Disease Should Not Matter, Brisbane, QLD, Australia, 2–4 November 2022. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.13868
2022
Conference Publication
76. “Gadgets and gizmos aplenty!” Dressing and securing peripherally inserted central catheters to prevent infection and failure
Rickard, Claire, Larsen, Emily, Marsh, Nicole, McGrail, Matthew, Ullman, Amanda, Kleidon, Tricia, Chan, Ray, Byrnes, Joshua, Mollee, Peter, Paterson, David, Chopra, Vineet, Stone, Leanne, Tapsall, Doreen, Keogh, Samantha, Gavin, Nicole, McCarthy, Sandie, Alexandrou, Evan, Choudhury, M.A., Corley, Amanda, Schults, Jessica, Ray-Barruel, Gillian and Geoffrey Playford, E. (2022). 76. “Gadgets and gizmos aplenty!” Dressing and securing peripherally inserted central catheters to prevent infection and failure. 2022 ACIPC International Conference, Sydney, NSW Australia, 13 - 16 November 2022. Amsterdam, Netherlands: Elsevier BV. doi: 10.1016/j.idh.2022.09.034
2022
Journal Article
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study
Landgren, Ola, Weisel, Katja, Rosinol, Laura, Touzeau, Cyrille, Turgut, Mehmet, Hajek, Roman, Mollee, Peter, Kim, Jin Seok, Shu, Natalie, Hu, Xuguang, Li, Chuang and Usmani, Saad Z. (2022). Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. British Journal of Haematology, 198 (6), 988-993. doi: 10.1111/bjh.18233
2022
Journal Article
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
McQuilten, Zoe, Wellard, Cameron, Moore, Elizabeth, Augustson, Bradley, Bergin, Krystal, Blacklock, Hilary, Harrison, Simon, Ho, P. Joy, King, Tracy, Quach, Hang, Mollee, Peter, Rosengarten, Brian, Walker, Patricia, Wood, Erica, Spencer, Andrew and Australian and New Zealand Myeloma and Related Diseases Registry (2022). Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). British Journal of Haematology, 198 (5), 830-837. doi: 10.1111/bjh.18324
2022
Journal Article
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: results from the ANDROMEDA study
Sanchorawala, Vaishali, Palladini, Giovanni, Minnema, Monique C., Jaccard, Arnaud, Lee, Hans C., Gibbs, Simon, Mollee, Peter, Venner, Christopher, Lu, Jin, Schönland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, María Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Gries, Katharine S., Fastenau, John, Tran, Nam Phuong, Qin, Xiang, Vasey, Sandra Y., Weiss, Brendan M., Vermeulen, Jessica ... Wechalekar, Ashutosh D. (2022). Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: results from the ANDROMEDA study. American Journal of Hematology, 97 (6), 719-730. doi: 10.1002/ajh.26536
2022
Journal Article
An individualized exercise intervention for people with multiple Myeloma—study protocol of a randomized waitlist-controlled trial
Nicol, Jennifer L., Woodrow, Carmel, Cunningham, Brent J., Mollee, Peter, Weber, Nicholas, Smith, Michelle D., Nicol, Andrew J., Gordon, Louisa G., Hill, Michelle M. and Skinner, Tina L. (2022). An individualized exercise intervention for people with multiple Myeloma—study protocol of a randomized waitlist-controlled trial. Current Oncology, 29 (2), 901-923. doi: 10.3390/curroncol29020077
2022
Journal Article
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines
Sanchorawala, Vaishali, Boccadoro, Mario, Gertz, Morie, Hegenbart, Ute, Kastritis, Efstathios, Landau, Heather, Mollee, Peter, Wechalekar, Ashutosh and Palladini, Giovanni (2022). Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid, 29 (1), 1-7. doi: 10.1080/13506129.2021.2002841
2022
Journal Article
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
Kalff, Anna, Khong, Tiffany, Ramachandran, Malarmathy, Joy Ho, P., Mollee, Peter, D’Rozario, James, Taylor, Kerry, Estell, Jane, Norton, Sam, Kemp, Roslyn, Mitchell, Andrew J., Reynolds, John, Kennedy, Nola, Quach, Hang and Spencer, Andrew (2022). Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). Haematologica, 107 (1), 321-325. doi: 10.3324/haematol.2021.278655
2022
Conference Publication
Predictors of outcomes in patients with ATTRwt cardiac amyloidosis
Mew, T., Mollee, P. and Korczyk, D. (2022). Predictors of outcomes in patients with ATTRwt cardiac amyloidosis. 70th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Gold Coast, QLD Australia, 11-14 August 2022. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2022.06.115
2021
Journal Article
The role of a routine bone marrow biopsy in autoimmune hemolytic anemia for the detection of an underlying lymphoproliferative disorder
Campbell, Ashlea, Podbury, Bridget, Yue, Mimi, Mollee, Peter, Bird, Robert and Hapgood, Greg (2021). The role of a routine bone marrow biopsy in autoimmune hemolytic anemia for the detection of an underlying lymphoproliferative disorder. HemaSphere, 6 (1), e674-e674. doi: 10.1097/hs9.0000000000000674
2021
Journal Article
Catheter-associated bloodstream infection in patients with cancer: comparison of left- and right-sided insertions
Jones, M., Okano, S., Looke, D., Kennedy, G., Pavilion, G., Clouston, J., Van Kuilenburg, R., Geary, A., Joubert, W., Eastgate, M. and Mollee, P. (2021). Catheter-associated bloodstream infection in patients with cancer: comparison of left- and right-sided insertions. Journal of Hospital Infection, 118, 70-76. doi: 10.1016/j.jhin.2021.10.008
2021
Conference Publication
Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study
Comenzo, Raymond, Palladini, Giovanni, Kastritis, Efsthathios, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Dispenzieri, Angela, Lee, Hans C., Sanchorawala, Vaishali, Gibbs, Simon D., Mollee, Peter, Venner, Chris P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Teresa Cibeira, M., Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Tran, Nam Phuong, Xin, Xiang, Khaled, Samer, Vermeulen, Jessica and Merlini, Giampaolo (2021). Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study. 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. WASHINGTON: AMER SOC HEMATOLOGY. doi: 10.1182/blood-2021-146820
2021
Conference Publication
A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)
Mollee, Peter, Reynolds, John, Janowski, Wojciech, Quach, Hang, Campbell, Philip, Gibbs, Simon D., Lee, Sophie, D'Rozario, James, Taylor, Kerry, Cochrane, Tara, Wallington-Beddoe, Craig Thomas, Kwok, Fiona, Weber, Nicholas, Kerridge, Ian H., Weston, Helen, Ho, P. Joy, Horvath, Noemi, Yuen, Flora and Spencer, Andrew (2021). A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-152500
2021
Conference Publication
Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
Li Chai, Khai, Wellard, Cameron, Moore, Elizabeth M., Augustson, Bradley, Bapat, Akshay, Blacklock, Hilary Anne, Cooke, Rachel Elizabeth, Forsyth, Cecily, Hamad, Nada, Harrison, Simon J., Ho, Phobe Joy, Hocking, Jay, Kerridge, Ian H., King, Tracy, McCaughan, Georgia J., Mollee, Peter, Morrissey, Orla, Murphy, Nicholas E., Quach, Hand, Tan, Xuan Ni, Wong, Kimberly, Spencer, Andrew, Wood, Erica M. and McQuilten, Zoe (2021). Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta Ga, Dec 11-14, 2021. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2021-147622
2021
Journal Article
Management and outcomes of diffuse large B-cell lymphoma post-transplant lymphoproliferative disorder in the era of PET and Rituximab: a multicenter study from the Australasian Lymphoma Alliance
Boyle, Stephen, Tobin, Joshua W. D., Perram, Jacinta, Hamad, Nada, Gullapalli, Veena, Barraclough, Allison, Singaraveloo, Lydia, Han, Min-Hi, Blennerhassett, Richard, Nelson, Niles, Johnston, Anna M., Talaulikar, Dipti, Karpe, Krishna, Bhattacharyya, Abir, Cheah, Chan Yoon, Subramoniapillai, Elango, Bokhari, Waqas, Lee, Cindy, Hawkes, Eliza A., Jabbour, Andrew, Strasser, Simone, Chadban, Steven J., Brown, Christina, Mollee, Peter and Hapgood, Greg (2021). Management and outcomes of diffuse large B-cell lymphoma post-transplant lymphoproliferative disorder in the era of PET and Rituximab: a multicenter study from the Australasian Lymphoma Alliance. HemaSphere, 5 (11) e648, 1-8. doi: 10.1097/hs9.0000000000000648
2021
Journal Article
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia
Creeper, Katherine, Augustson, Bradley, Kusel, Kieran, Fulham, Michael J., Ho, Joy, Quach, Hang, Mollee, Peter, Weber, Nicholas, Talaulikar, Dipti, Johnston, Anna, Murphy, Nick, Joshua, Douglas, Ward, Christopher, Ling, Silvia, Gibson, John, Szer, Jeff, Harrison, Simon, Zannettino, Andrew, Jaksic, Wilfrid, Lee, Cindy, Spencer, Andrew, Kalff, Anna, Szabo, Ferenc, Romeril, Ken, Chan, Henry, Gibbs, Simon, Horvath, Noemi and Prince, H. Miles (2021). Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 51 (10), 1707-1712. doi: 10.1111/imj.15457
2021
Journal Article
Daratumumab-based treatment for immunoglobulin light-chain amyloidosis
Kastritis, Efstathios, Palladini, Giovanni, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Lee, Hans C., Sanchorawala, Vaishali, Gibbs, Simon, Mollee, Peter, Venner, Christopher P., Lu, Jin, Schönland, Stefan, Gatt, Moshe E., Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Huart, Antoine, Dimopoulos, Meletios A., Bhutani, Divaya, Waxman, Adam J., Goodman, Stacey A., Zonder, Jeffrey A. ... Comenzo, Raymond L. (2021). Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. New England Journal of Medicine, 385 (1), 46-58. doi: 10.1056/NEJMoa2028631
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: